secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2023-06-27T23:59:59+00:00
Accession:  0001104659-23-075241
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute to initiate Phase 3 for RZ358 in congenital HI outside US in Q4 2023; FDA restrictions prevent US inclusion
--------------------------------------------------------------------------------

- Phase 3 sunRIZE study of RZ358 planned in Europe/ex-US starting Q4 2023; topline results expected 1H 2025.
- FDA maintained age restriction (12+ years) and re-imposed dose cap based on rat toxicology; US inclusion currently infeasible.
- Company evaluating nonclinical studies to address FDA concerns in parallel with ex-US Phase 3; cash $129M sustains ops through Q3 2025.
- Phase 2b RIZE study showed RZ358 generally safe, well-tolerated, and effective in improving hypoglycemia.
- Estimated congenital HI prevalence >10,000 in primary markets; >50% lack adequate treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465923075241/0001104659-23-075241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465923075241/tm2319715d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-075241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer